BioSpace News Archive

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce that Jeffery Baker , Ph.D., Tim Charlebois , Ph.D., Roger Hart , Ph.D., and Stefanie Pluschkell , Ph.D. have recently joined the Institute as NIIMBL Senior Fellows enhancing that expertise of the organization

Augmedix, Inc. (Nasdaq: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced it will report financial results for the third quarter 2021 on Tuesday, November 9, 2021, after market close.

Zymergen Inc. (Nasdaq: ZY) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd, 2021.

Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF).

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced that it plans to release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), today announced that the stockholders of Bioventus approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix in connection with the previously announced Agreement and Plan of Merger, dated July 29, 2021,

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 48,800 shares of the Company’s common stock at an exercise price per share of $34.38, which was the closing price on October 25, 2021.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the publication of its study “Precision neoantigen discovery using large-scale immunopeptidomes and composite modeling of MHC peptide presentation,” in the Immunopeptidomics Special Issue of the journal Molecular & Cellular Proteomics.

BD, a leading global medical technology company, announced that it will host a virtual investor day on Friday, Nov. 12, 2021 at 8 a.m., which will last for approximately four hours.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (“PF Argentum”) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”) at the special meeting of Trillium securityholders today.